Dejan Juric

Dejan Juric

UNVERIFIED PROFILE

Are you Dejan Juric?   Register this Author

Register author
Dejan Juric

Dejan Juric

Publications by authors named "Dejan Juric"

Are you Dejan Juric?   Register this Author

45Publications

1574Reads

45Profile Views

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.

Cell Chem Biol 2019 Aug 6;26(8):1067-1080.e8. Epub 2019 Jun 6.

Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2019.05.005DOI Listing
August 2019

Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.

Breast Cancer Res Treat 2019 Jun 27;175(3):649-658. Epub 2019 Mar 27.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05206-y
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05206-yDOI Listing
June 2019

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

N Engl J Med 2019 05;380(20):1929-1940

From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l'Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) - all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt - both in Germany (S.L.); UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Aichi Cancer Center, Nagoya (H.I.), Kanagawa Cancer Center, Yokohama (T.Y.), Saitama Cancer Center, Saitama (K.I.), and National Hospital Organization Hokkaido Cancer Center, Sapporo (M.T.) - all in Japan; Istituto Oncologico Veneto and the Departments of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy (P.C.); Vanderbilt University, Nashville (I.A.M.); Chaim Sheba Medical Center, Tel Hashomer, Israel (B.K.); National Taiwan University Hospital, Taipei (Y.-S.L.); Novartis Pharma, Basel, Switzerland (D.M., C.W.); Novartis Pharmaceuticals, East Hanover, NJ (S.H.); and Massachusetts General Hospital Cancer Center, Boston (D.J.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1813904
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1813904DOI Listing
May 2019

A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.

Breast Cancer Res Treat 2019 Apr 3;174(3):605-613. Epub 2019 Jan 3.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05079-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440812PMC
April 2019

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2017 Jul 14;35(19):2141-2148. Epub 2017 Mar 14.

Aditya Bardia, Steven J. Isakoff, and Dejan Juric, Massachusetts General Hospital Cancer Center; Aditya Bardia, Steven J. Isakoff, Dejan Juric, and Sara M. Tolaney, Harvard Medical School; Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA; Ingrid A. Mayer, Vandana Abramson, and Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jennifer R. Diamond and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Rebecca L. Moroose and Nikita C. Shah, University of Florida Health Cancer Center, Orlando, FL; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center; Joyce O'Shaughnessy, US Oncology, Dallas, TX; Kevin Kalinsky, Columbia University Herbert Irving Comprehensive Cancer Center; Allyson J. Ocean and Linda T. Vahdat, Weill Cornell Medicine, New York, NY; Michael Guarino, Helen F. Graham Cancer Center, Newark, DE; William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559902PMC
July 2017

Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.

J Nucl Med 2016 09 14;57(9):1413-9. Epub 2016 Apr 14.

Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.115.169417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093919PMC
September 2016

Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates.

Sci Transl Med 2014 Jan;6(219):219ra9

Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3007361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063286PMC
January 2014

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

J Clin Oncol 2012 Mar 23;30(8):765-6. Epub 2012 Jan 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.39.6390DOI Listing
March 2012

Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.

Methods Mol Biol 2007 ;377:187-202

Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-59745-390-5_12DOI Listing
August 2007

Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.

J Clin Oncol 2007 Apr 20;25(11):1341-9. Epub 2007 Feb 20.

Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.09.3534DOI Listing
April 2007

Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.

Genes Chromosomes Cancer 2006 04;45(4):365-74

Oncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20300DOI Listing
April 2006

Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.

J Clin Oncol 2006 Jan 19;24(2):274-87. Epub 2005 Dec 19.

Division of Oncology, Center for Clinical Sciences Research, Institute for Computational and Mathematical Engineering, Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.02.9405DOI Listing
January 2006

Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures.

Proc Natl Acad Sci U S A 2005 Dec 23;102(49):17763-8. Epub 2005 Nov 23.

Oncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.0509082102
Publisher Site
http://dx.doi.org/10.1073/pnas.0509082102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1308932PMC
December 2005

Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.

Cancer Res 2005 Oct;65(19):8679-89

Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California 94305-5151, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-05-1204DOI Listing
October 2005

Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line.

Cancer Res 2005 Oct;65(20):9388-97

Division of Oncology, Department of Medicine and Program in Cancer Biology, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-4133DOI Listing
October 2005

High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

Cancer Res 2005 May;65(10):4088-96

Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California 94305-5151, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-4229DOI Listing
May 2005